Stockscreener 앱 받기
9.40
1.57%
-0.15
시간 외 거래:
9.40
Zevra Therapeutics Inc 주식(ZVRA)의 최신 뉴스
CFO at Zevra (NASDAQ: ZVRA) receives 300,000-share option grant - Stock Titan
Zevra Therapeutics appoints Justin Renz as CFO - MSN
Nio, Zevra Therapeutics, Vertex Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewswire Inc.
BTIG initiates Zevra Therapeutics stock with buy on Miplyffa outlook - Investing.com Nigeria
R. LaDuane Clifton (ZVRA) files Form 144 showing 11,000‑ and 3,000‑share sales - Stock Titan
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million and Settles Delaware Lawsuit 1 - Minichart
Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap UpStill a Buy? - MarketBeat
Zevra Therapeutics Agrees to Sell SDX Portfolio to Commave Therapeutics for $50 Million - marketscreener.com
Zevra Shares Jump After Selling SDX Portfolio For $50M - Benzinga
BTIG initiates Zevra Therapeutics stock with buy on Miplyffa outlook By Investing.com - Investing.com Australia
Zevra Therapeutics (NASDAQ:ZVRA) Now Covered by BTIG Research - MarketBeat
Zevra Therapeutics (ZVRA) Sells Serdexmethylphenidate Portfolio to Commave for $50 Million - GuruFocus
Zevra Sells SDX Portfolio and Resolves Litigation - TipRanks
Zevra Therapeutics, Inc. $ZVRA Shares Bought by Kingdon Capital Management L.L.C. - MarketBeat
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million - Quiver Quantitative
Zevra Therapeutics Sells Sdx Portfolio To Commave Therapeutics For $50 Million - TradingView
Zevra Sells SDX Portfolio to Commave for $50 Million, Ends Azstarys Pact and Repays Credit Facility - TradingView
ZVRA: BTIG Initiates Coverage with a "Buy" Rating and $23.00 PT - GuruFocus
Zevra (Nasdaq: ZVRA) sells SDX portfolio for $50M and repays $63M loan - Stock Titan
BTIG initiates coverage of Zevra Therapeutics (ZVRA) with buy recommendation - MSN
Zevra jumps 19% after Q4 EPS tops consensus estimates - MSN
A Look At Zevra Therapeutics (ZVRA) Valuation After Profitability And MIPLYFFA Commercial Progress - Sahm
Zevra Therapeutics (NASDAQ:ZVRA) Cut to "Hold" at Wall Street Zen - MarketBeat
Aug Macro: Is Zevra Therapeutics Inc backed by strong institutional buying2026 Key Highlights & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Zevra Therapeutics, Inc.Common Stock (NQ: ZVRA - The Chronicle-Journal
Trading Systems Reacting to (ZVRA) Volatility - Stock Traders Daily
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR) - The Globe and Mail
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today - AOL.com
Analysts Set Expectations for ZVRA Q1 Earnings - MarketBeat
ZVRA Stock Price, Quote & Chart | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
Zevra Therapeutics Faces Partnership Hurdles That Could Delay Drug Development and Pressure Financing - The Globe and Mail
Trading Action: Should I set a stop loss on Zevra Therapeutics IncEarnings Beat & Daily Profit Focused Screening - baoquankhu1.vn
Is Zevra Therapeutics (ZVRA) Pricing Reflecting Its Strong Multi‑Year Share Price Performance - Yahoo Finance
WGS, Zevra Partner to Launch Genetic Testing for Niemann-Pick Type C - Zacks Investment Research
Zevra at Citizens Life Sciences: Strategic Growth and Expansion By Investing.com - Investing.com Canada
Zevra Therapeutics (NASDAQ:ZVRA) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
ZVRA: MIPLYFFA drives rare disease growth with strong revenue, global expansion, and pipeline progress - TradingView
Can Zevra Therapeutics (ZVRA) Turn NPC Genetic Testing Access Into a Durable Rare-Disease Edge? - Yahoo Finance
Zevra Therapeutics (ZVRA) Gets a Buy from Roth MKM - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Zevra Therapeutics (ZVRA) and Cooper Co (COO) - The Globe and Mail
Brokers Offer Predictions for ZVRA Q3 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Jazz Pharmaceuticals (JAZZ) and Talkspace (TALK) - The Globe and Mail
Zevra Therapeutics (ZVRA) Profit Swing To US$77.6m TTM Tests Rare Disease Bull Case - simplywall.st
Why Is Zevra Therapeutics Stock Trading Higher Today? - Bitget
Why Zevra Therapeutics stock zoomed 21% higher today - MSN
Why Zevra Therapeutics Stock Zoomed 21% Higher Today - Yahoo Finance
Zevra Therapeutics Appoints Justin Renz as New CFO - The Globe and Mail
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Benzinga
Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model (NASDAQ:ZVRA) - Seeking Alpha
GeneDx Holdings Corp. to Launch Genetic Testing Program with Zevra Therapeutics, Inc. to Support Patients with Suspected Niemann-Pick Disease Type C - marketscreener.com
Zevra Therapeutics partners with GeneDx to launch genetic testing for NPC in U.S. - Traders Union
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C - Yahoo Finance
Guggenheim raises Zevra Therapeutics stock price target to $23 By Investing.com - Investing.com Australia
US Premarket Movers: BioNTech, Kohl’s, Teladoc, Vertex, Zevra - Bloomberg.com
Guggenheim raises Zevra Therapeutics stock price target to $23 - Investing.com
Zevra Therapeutics price target raised to $23 from $22 at Guggenheim - TipRanks
1.20%
0.06%
자본화:
|
볼륨(24시간):